Literature DB >> 12230277

Intravesical treatment of severe bacillus Calmette-Guerin cystitis.

J Palou1, L Rodríguez-Villamil, A Andreu-Crespo, J Salvador-Bayarri, J Vicente-Rodríguez.   

Abstract

OBJECTIVE: Intravesical instillation of bacillus Calmette-Guerin (BCG) is an established treatment of carcinoma in situ and recurrent superficial bladder tumours. The inflammatory reaction due to BCG provokes cystitis of short duration as a frequent side effect. When the symptomatology is severe and long-lasting, different systemic treatments have been administered with varying degrees of efficacy.
MATERIAL AND METHODS: We have studied the treatment of severe BCG cystitis with a anaesthetic anti-inflammatory solution administered by intravesical instillations to 16 patients.
RESULTS: Good results were obtained in 94% of the cases, with immediate clinical improvement in terms of pain and urinary symptoms, and with no side effects.
CONCLUSIONS: This treatment is inexpensive and easy to administer. We consider that it offers a useful option to solve an infrequent but very annoying problem for the patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12230277     DOI: 10.1023/a:1019507104741

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail.

Authors:  R Wittes; L Klotz; U Kosecka
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

2.  Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.

Authors:  J A Martínez-Piñeiro; J Jiménez León; L Martínez-Piñeiro; L Fiter; J A Mosteiro; J Navarro; M J García Matres; P Cárcamo
Journal:  J Urol       Date:  1990-03       Impact factor: 7.450

3.  Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).

Authors:  J H Günther; M Frambach; I Deinert; S Brandau; D Jocham; A Böhle
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

4.  [Drug-induced fever caused by prophylactic isoniazid in bladder instillations with BCG].

Authors:  J Palou Redorta; J E Batista Miranda; P Laguna Pes; J Vicente Rodríguez
Journal:  Actas Urol Esp       Date:  1992-03       Impact factor: 0.994

5.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

6.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.

Authors:  P M van der Meijden; B van Klingeren; P A Steerenberg; L C de Boer; W H de Jong; F M Debruyne
Journal:  J Urol       Date:  1991-08       Impact factor: 7.450

9.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

Authors:  S A Brosman
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

10.  Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.

Authors:  H Zincke; D C Utz; W F Taylor; R P Myers; F J Leary
Journal:  J Urol       Date:  1983-03       Impact factor: 7.450

  10 in total
  1 in total

1.  Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.

Authors:  Wujiang Liu; David P Evanoff; Xiaohong Chen; Yi Luo
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.